GlassScriptPhysician profile
Calida Tam
NPI 1346003118
$3,058.75
in general payments reported to CMS, 2019-2025
20 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,071 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546.64 | 2024-2025 | |
| Novo Nordisk INC | $481.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $432.78 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $409.23 | 2024-2025 | |
| Lilly USA, LLC | $266.96 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $214.42 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.91 | 2025 | Jardiance |
| Pfizer INC. | $139.94 | 2025 | |
| Vanda Pharmaceuticals INC. | $102.88 | 2024-2025 | Fanapt |
| Hologic Sales and Service, LLC | $50.01 | 2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $48.86 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $43.08 | 2025 | Zoryve |
| Corium, LLC | $33.49 | 2024 | Azstarys |
| Daiichi Sankyo INC. | $32.78 | 2024-2025 | Injectafer |
| Exact Sciences Corporation | $23.98 | 2025 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $23.93 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $21.01 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $15.07 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $13.54 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calida Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.